JPMorgan International Research Enhanced Equity ETF (JIRE)

NYSEArca • Currently up 19.22 (+29.16%) in today's trading session

1 member of Congress has disclosed 1 trade in JPMorgan International Research Enhanced Equity ETF (JIRE) via STOCK Act filings. The most recent disclosure was a sale by Derek Schmidt on 29 October 2026. Aggregate disclosed activity totals roughly $75K in sales (midpoint estimates from bracketed disclosure amounts).

JPMorgan International Research Enhanced Equity ETF is currently trading at $85.13, positioned at 94% of its 52-week range ($70.87 – $86.07).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Free asset at sign up • Eligible regions only
Copy PortfolioClaim Free Asset
Live portfolio tracking
Automatic rebalancing

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Not available in the US.

Past Performance is not an indication of future results.

*Free asset promotion available at sign up in eligible regions only. Terms and conditions apply.

Current Price
$85.13
24h Change
+19.22 (+29.16%)
52 Week Range
$70.87—$86.07
View on NASDAQ

JPMorgan International Research Enhanced Equity ETF Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for JIRE

Select to highlight on chart
0 transactions
Compliance: 0%
No data

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$11.35B

Volume

895.09K

Beta

0.80

P/E Ratio

19.00

Fundamentals

EPS

$4.48

Div. Yield

2.63%

Open

$85.03

Day Range

$84.92 — $85.28

Company Information

Sector
Financial Services
Industry
Asset Management - Global
Exchange
AMEX · USD
Country
US
IPO Date
2022-06-15
Website
am.jpmorgan.com/us/en/asset-management/adv/products/jpmorgan-international-research-enhanced-equity-etf-etf-shares-46641q134

This fund typically directs at least 80% of its capital into equity investments. Its core objective is to surpass the long-term returns of the MSCI EAFE Index, while meticulously maintaining a risk profile that mirrors the index's, particularly conce...

No earnings data available for this stock.

Dividends

Dividend History

16 Dec 2025
Amount $2.2393
24 Dec 2024
Amount $1.7711
19 Dec 2023
Amount $1.5991
20 Dec 2022
Amount $1.3106

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations
No similar stocks found
No congressional trading patterns available for recommendations

Frequently Asked Questions about JIRE

Which members of Congress have traded JIRE?
1 member of Congress has disclosed 1 trade in JPMorgan International Research Enhanced Equity ETF (JIRE) under the STOCK Act: Derek Schmidt.
When was JIRE most recently disclosed by Congress?
The most recent JIRE disclosure was a sale by Derek Schmidt on 29 October 2026.
What is the total disclosed congressional trading volume for JIRE?
Members of Congress have disclosed approximately $75K in JIRE sales (midpoint estimate derived from the bracketed amount ranges used in STOCK Act filings).
How can I track new congressional trades in JIRE?
This JIRE page updates as soon as new STOCK Act disclosures are filed for JPMorgan International Research Enhanced Equity ETF. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
PoliticiansBillsArticlesPortfoliosPricingAboutLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
Pelosi Tracker is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office or her representatives, or with any other member of Congress. Any use of her name is solely for the purpose of discussing publicly available information.The information provided by Pelosi Tracker is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.